Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in this Application:

Listing of Claims:

1. (Currently Amended) A composition ~~for the treatment, prevention or management of a condition in primates, especially humans~~ comprising a phenolic antioxidant-chromium complex that is therapeutic for treating hyperglycemia, wherein the phenolic antioxidant has no pro-oxidation activity.

2. (Currently Amended) The composition of claim 1 wherein the hyperglycemia is due to a diabetic condition~~condition is Type 2 diabetes or non-insulin dependent diabetes mellitus~~.

3. (Canceled)

4. (Canceled)

5. (Original) The composition of claim 1 wherein the phenolic antioxidant is of plant origin.

6. (Original) The composition of claim 1 wherein the chromium content in the complex is 0.01 to 20% of the complex.

7. (Original) The composition of claim 6 wherein the chromium content in the complex is from 0.02 to 10%.

8. (Currently Amended) The composition of claim 1 wherein the chromium is trivalent ~~in nature~~.

9. (Currently Amended) The composition of claim 1 wherein the phenolic antioxidants ~~include~~ comprises low molecular weight hydrolyzable tannins having a molecular weight below 2,000.

10. (Original) The composition of claim 9 wherein the phenolic antioxidant is obtained from the genus Phyllanthus, Terminalia, Gardenia, Geranium, Erodium or Tamarix.

11. (Currently Amended) The composition of claim 9 wherein the hydrolyzable tannins ~~are~~ is obtained from Phyllanthus emblica (syn. Emblica officinalis), Phyllanthus amarus, Phyllanthus flexusus, other Phyllanthus species, Terminalia bellerica, ~~and~~ other Terminalia species, Erodium pelagonium, Geranium thumbergi, Tamarix aphyla or ~~an~~other Tamarix species.

12. (Canceled)

13. (Currently Amended) The composition of claim 11 wherein the hydrolyzable tannins ~~are~~ is obtained from the Phyllanthus emblica fruit.

14. (Currently Amended) ~~A~~ The composition of claim 1 ~~comprising~~ wherein the phenolic antioxidant ~~chromium complex(s) of~~comprises oxygenated dibenzo-α-pyrone (DBP) or ~~its conjugates~~a DBP conjugate~~, including dimers and oligomers~~ and fulvic acids ~~for the treatment, prevention or management of Type 2 diabetes or glucose tolerance in primates, especially humans~~.

15. (Currently Amended) The composition of claim 14 wherein the oxygenated dibenzo-α-pyrone (DBP) or ~~its~~ DBP conjugates, ~~including~~ comprises dimers and oligomers ~~and fulvic acids are obtained from purified Shilajit~~.

16. (Currently Amended l) ~~A~~ The composition of claim 1, ~~comprising chromium complex(s) of~~wherein the phenolic anti-oxidant ~~fractions of~~is obtained from Phyllanthus emblica and/~~or~~ purified Shilajit~~, for the treatment, prevention or management of Type 2 diabetes or glucose intolerance~~.

17. (Original) The composition of claim 1 wherein the phenolic antioxidant-chromium complex is prepared by reacting a trivalent chromium salt with a phenolic antioxidant(s).

18. (Original) The composition of claim 17 wherein the phenolic antioxidant-chromium complex is prepared by reacting chromium chloride, acetate or formate with a phenolic antioxidant(s) in an aqueous system.

19. (Original) The composition of claim 18 wherein the phenolic antioxidant-chromium complex is prepared by reacting chromium chloride, acetate or formate with low molecular weight tannins having a molecular weight below 2,000.

20. (Currently Amended) The composition of claim 17 wherein the phenolic antioxidant-chromium complex is prepared by reacting chromium chloride, acetate or formate with ~~oxygenated dibenzo-α-pyrone (DBP) or its conjugates, including dimers and oligomers and fulvic acids of~~ phenolic antioxidant from purified Shilajit in an aqueous system.

21. (Original) The composition of claim 17 wherein the phenolic antioxidant-chromium complex is obtained by spray, freeze, tray or vacuum drying.

22. (Original) A formulation of the composition of claim 1 wherein the phenolic antioxidant-chromium complex is combined with a pharmaceutically or nutritionally acceptable excipient.

23. (Cancelled)

24. (Currently Amended) The composition of claim 1 ~~which also includes~~further comprising an ~~added~~ additional active ingredient.

25. (Currently Amended) The composition of claim 24 wherein ~~said added~~the additional active ingredient is an antioxidant, vitamin, carnitine, carnosine, N-acetyl-L-cysteine, biotin, polycosanol, aminoguanidine, ~~a~~ fatty acid or plant extract, or mixtures thereof.

26. (Currently Amended) The composition of claim 7 wherein the chromium content in the complex is from 1 to 8% of the complex.

27. (Original) The composition of claim 19 wherein the molecular weight of said tannins is below 1,000.

28. (Currently Amended) A method of treatment for hyperglycemia ~~treating, preventing or managing a condition in primates, especially humans~~ which comprises ~~treating~~ administering to a mammal ~~said primate, especially human with~~ the composition of claim 1.

29. (Currently Amended) The~~A~~ method of claim 28 wherein the hyperglycemia is the result of a diabetic condition ~~said condition is Type 2 diabetes or glucose intolerance~~.

30. (Currently Amended) The~~A~~ formulation of claim 22 wherein the phenolic antioxidant-chromium complex ~~having~~ has 10 to 1,000 μg of chromium content ~~is combined with a pharmaceutically or nutritionally acceptable excipient to improve insulin sensitivity, reduce blood glucose, glycated hemoglobin, reduce total cholesterol and low density lipids in primates, especially humans~~.

31. (Currently Amended) The composition of claim 17 wherein the phenolic antioxidant-chromium complex is prepared by dry blending ~~a trivalent chromium salt or a complex with a phenolic antioxidant(s)~~.

32. (Currently Amended) The composition of claim 31 wherein the ~~phenolic antioxidant~~ chromium ~~complex~~ is ~~prepared by dry blending~~derived from chromium chloride, acetate, ~~or~~ formate, picolinate, nicotinate or polynicotinate ~~with a phenolic antioxidant(s)~~.

33. (Currently Amended) The composition of claim 31 wherein the ~~phenolic antioxidant chromium complex is prepared by dry blending chromium chloride, acetate, formate, nicotinate, polynicotinate or picolinate with~~ phenolic antioxidant is oxygenated dibenzo-α-pyrone (DBP), ~~or~~a DBP conjugate ~~its conjugates, including dimmers and oligomers and~~ or fulvic acids of purified Shilajit.

34. (Currently Amended) ~~A~~ The compositionformulation of claim 31 wherein the phenolic antioxidant-chromium ~~blend~~ complex has ~~having~~ 10 to 1,000 μg of chromium and is combined with a pharmaceutically or nutritionally acceptable excipient ~~to improve Type 2 diabetes, glucose intolerance, insulin sensitivity, reduce blood glucose, glycated hemoglobin, reduce total cholesterol and low density lipid in primates, especially humans~~.

35. (Currently Amended) ~~A~~ The method of claim 28 wherein the composition ~~pharmaceutical or nutritional preparation of claim 34~~ is administered once or twice a day ~~to a primate, especially human~~.

36. (New) The composition of claim 15, wherein the oxygenated dibenzo-α-pyrone (DBP), DBP conjugate, and fulvic acid are obtained from purified Shilajit.

37. (New) The composition of claim 33, wherein the oxygenated dibenzo-α-pyrone (DBP) and DBP conjugate comprises dimers and oligomers.